Acute Lymphoblastic Leukemia Registry at Asan Medical Center
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01761682 |
Recruitment Status :
Terminated
(The PI resigned the institute, and the rest investigators at the institute decided to terminate the study.)
First Posted : January 7, 2013
Last Update Posted : July 20, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Leukemia, Acute Lymphoblastic Precursor B-Cell Lymphoblastic Leukemia Leukemia, Biphenotypic, Acute Leukemia, Lymphoblastic, Acute, Philadelphia-Positive Lymphoblastic Lymphoma | Other: Diagnosed as ALL |
- Acquisition of informed concent form
-
Data acquisition from medical record including
- demographic / disease-associated factors
- details of treatment, and its results
- complications during treatment
- genetic data
- survival outcome (upto 10 years)
- Accumulation of data for 30 years
- Use of data for other retrospective analysis (including Asan Medical center Cell Banking basic data)
Study Type : | Observational [Patient Registry] |
Actual Enrollment : | 200 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 10 Years |
Official Title: | Prospective Observational Cohort Registry for Patients With Acute Lymphoblastic Leukemia at Asan Medical Center |
Study Start Date : | January 2013 |
Actual Primary Completion Date : | May 2016 |
Actual Study Completion Date : | May 2016 |

Group/Cohort | Intervention/treatment |
---|---|
Ph-ALL
Diagnosed as ALL with Philadelphia-negative
|
Other: Diagnosed as ALL
All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
Other Name: Diagnosed as acute lymphoblastic leukemia |
Ph+ALL
Diagnosed as ALL with Philadelphia-positive (including biphenotypic acute leukemia with Philadelphia-positive)
|
Other: Diagnosed as ALL
All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
Other Name: Diagnosed as acute lymphoblastic leukemia |
Other ALL
Diagnosed as ALL of other type, including Burkitt leukemia
|
Other: Diagnosed as ALL
All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
Other Name: Diagnosed as acute lymphoblastic leukemia |
- Overall survival [ Time Frame: 10 year ]
- Event-free survival [ Time Frame: 10 years ]Definition of events will be as 'relapse', 'death from any cause'. Relapse will be defined as hematologic relapse and molecular relapse, respectively when the patient is diagnosed as Philadelphia-positive acute lymphoblastic leukemia
- Relapse-free survival [ Time Frame: 10 years ]Relapse will be defined as hematologic relapse and molecular relapse, respectively when the patient is diagnosed as Philadelphia-positive acute lymphoblastic leukemia
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- All patients who are diagnosed and/or treated as acute lymphoblastic leukemia at Asan Medical Center (including biphenotypic acute leukemia with Philadelphila-positive, Burkitt leukemia/lymphoma)
- 15 years of age and over
- All patients who give written consent according to guidelines at Asan Medical Center committee on human research
Exclusion Criteria:
- Patients who refuse to give consent to registering

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01761682
Korea, Republic of | |
Asan Medical Center | |
Seoul, Korea, Republic of, 138-736 |
Principal Investigator: | Dae-Young Kim, MD, PhD | Associate Professor |
Responsible Party: | Dae-Young Kim, Assistant Professor, Asan Medical Center |
ClinicalTrials.gov Identifier: | NCT01761682 |
Other Study ID Numbers: |
AMC-HEMREG-ALL |
First Posted: | January 7, 2013 Key Record Dates |
Last Update Posted: | July 20, 2018 |
Last Verified: | July 2018 |
Leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Biphenotypic, Acute Neoplasms by Histologic Type |
Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |